| Symbol | PLSE |
|---|---|
| Name | PULSE BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Surgical & Medical Instruments & Apparatus |
| Address | 3957 POINT EDEN WAY, HAYWARD, CA 94545 |
| Telephone | 510-906-4600 |
| Fax | — |
| — | |
| Website | https://www.pulsebiosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001625101 |
| Description | Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. Additional info from NASDAQ: |
Director Zanganeh Mahkam 🟢 acquired 44.5K shares (2 derivative) of PULSE BIOSCIENCES, INC. (PLSE) at $26.89 ($1.2M) Transaction Date: Jun 11, 2026 | Filing ID: 020722
Read moreDirector van den Broek Richard 🟢 acquired 38.4K shares (2 derivative) of PULSE BIOSCIENCES, INC. (PLSE) at $26.89 ($1.0M) Transaction Date: Jun 11, 2026 | Filing ID: 020719
Read moreDirector DUGGAN ROBERT W 🟢 acquired 42.5K shares (2 derivative) of PULSE BIOSCIENCES, INC. (PLSE) at $26.89 ($1.1M) Transaction Date: Jun 11, 2026 | Filing ID: 020717
Read moreDirector Soni Manmeet Singh 🟢 acquired 30.0K shares (1 derivative) of PULSE BIOSCIENCES, INC. (PLSE) at $26.89 Transaction Date: Jun 11, 2026 | Filing ID: 020715
Read moreDirector Sainz Maria 🟢 acquired 33.8K shares (2 derivative) of PULSE BIOSCIENCES, INC. (PLSE) at $26.89 Transaction Date: Jun 11, 2026 | Filing ID: 020713
Read morePulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Read moreNew Form 4/A - PULSE BIOSCIENCES, INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001437749-26-017478 <b>Size:</b> 7 KB
Read moreNew Form SCHEDULE 13D/A - PULSE BIOSCIENCES, INC. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001193125-26-222151 <b>Size:</b> 15 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07018596 | NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosc… | Na | Atrial Fibrillation Paroxysmal | Recruiting | 2026-04-06 | 2028-01-01 | ClinicalTrials.gov |
| NCT06959121 | CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System … | Na | Atrial Fibrillation | Recruiting | 2025-10-23 | 2028-12-01 | ClinicalTrials.gov |
| NCT07287176 | Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous … | Na | Thyroid Nodule | Recruiting | 2025-08-21 | 2027-06-30 | ClinicalTrials.gov |
| NCT06355063 | CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | Na | Atrial Fibrillation | Recruiting | 2024-07-31 | 2027-12-31 | ClinicalTrials.gov |
| NCT06696170 | CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for… | Na | Atrial Fibrillation Paroxysmal | Recruiting | 2024-07-25 | 2026-07-25 | ClinicalTrials.gov |
| NCT06117085 | CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid No… | Na | Thyroid Nodule (Benign) | Completed | 2023-04-13 | 2024-11-18 | ClinicalTrials.gov |
| NCT04918381 | CellFX Treat & Resect Low-Risk BCC Feasibility Study | Na | BCC - Basal Cell Carcinoma | Completed | 2021-06-02 | 2022-07-22 | ClinicalTrials.gov |
| NCT04738734 | CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts | Na | Warts | Completed | 2021-02-16 | 2022-09-25 | ClinicalTrials.gov |
| NCT04539886 | Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasi… | Na | Skin Lesion | Completed | 2020-09-28 | 2021-11-18 | ClinicalTrials.gov |
| NCT04554394 | CellFX System for the Treatment of Cutaneous Non-Genital Warts | Na | Warts | Completed | 2019-07-17 | 2020-12-01 | ClinicalTrials.gov |
| NCT04249115 | Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study | Na | Lesion Skin | Terminated | 2019-02-05 | 2021-04-22 | ClinicalTrials.gov |
| NCT04253418 | Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study | Na | Sebaceous Hyperplasia | Terminated | 2018-12-20 | 2021-03-26 | ClinicalTrials.gov |
| NCT03612570 | Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia | Na | Skin Lesion | Completed | 2018-06-28 | 2018-11-28 | ClinicalTrials.gov |
| NCT03846531 | Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study | Na | Lesion Skin | Completed | 2017-05-04 | 2018-05-22 | ClinicalTrials.gov |
| NCT02375373 | Effects of Adding Chickpeas to the American Diet (Long Term Study) | — | Inflammation | Completed | 2015-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02375347 | Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Compositio… | Na | Inflammation | Completed | 2015-03-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01519076 | A Safety Evaluation of the Use of Magnetic-guided Iron Particles | Phase1 | Ischemic Stroke | Terminated | 2012-06-01 | 2014-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT07018596 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| Nano-Pulse Stimulation (NPS) | Other | Approved | Sebaceous Hyperplasia | TERMINATED | NCT04253418 |
| Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED) | Other | Phase PHASE1 | Ischemic Stroke | TERMINATED | NCT01519076 |
| Observational Chickpea Diet | Other | Preclinical | Inflammation | COMPLETED | NCT02375373 |
| Chickpea Enhanced Diet (Short term) | Other | Approved | Inflammation | COMPLETED | NCT02375347 |
| CellFX System | Other | Approved | BCC - Basal Cell Carcinoma | COMPLETED | NCT04918381 |
| CellFX Device | Device | Approved | Warts | COMPLETED | NCT04554394 |
| Nano-Pulse Stimulation (NPS) | Other | Approved | Lesion Skin | COMPLETED | NCT03846531 |
| Nano-Pulse Stimulation (NPS) | Other | Approved | Lesion Skin | TERMINATED | NCT04249115 |
| Cryosurgery Liquid Nitrogen Sprayer | Procedure | Approved | Warts | COMPLETED | NCT04738734 |
| CellFX System Device | Device | Approved | Warts | COMPLETED | NCT04738734 |
| Nano-Pulse Stimulation Device | Device | Approved | Skin Lesion | COMPLETED | NCT03612570 |
| Intralesional Electrodesiccation | Other | Approved | Skin Lesion | COMPLETED | NCT04539886 |
| CellFX System | Other | Approved | Skin Lesion | COMPLETED | NCT04539886 |
| CellFX® Percutaneous Electrode (PE) System | Other | Approved | Thyroid Nodule (Benign) | COMPLETED | NCT06117085 |
| CellFX® nsPFA™ Cardiac Surgery System | Procedure | Approved | Atrial Fibrillation | RECRUITING | NCT06355063 |
| CellFX nsPFA Cardiac Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | NOT_YET_RECRUITING | NCT07018596 |
| CellFX® nsPFA™ Cardiac Surgery System | Procedure | Approved | Atrial Fibrillation | RECRUITING | NCT06959121 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | Other | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| nPulse Vybrance Percutaneous Electrode System | Other | Approved | Thyroid Nodule | RECRUITING | NCT07287176 |
| nPulse Vybrance Percutaneous Electrode System | DEVICE | Approved | Thyroid Nodule | RECRUITING | NCT07287176 |
| CellFX nsPFA Cardiac Catheter System | DEVICE | Approved | Atrial Fibrillation Paroxysmal | NOT_YET_RECRUITING | NCT07018596 |
| CellFX nano-pFA 360 Endocardial Ablation Catheter System | DEVICE | Approved | Atrial Fibrillation Paroxysmal | RECRUITING | NCT06696170 |
| CellFX® nsPFA™ Cardiac Surgery System | DEVICE | Approved | Atrial Fibrillation | RECRUITING | NCT06959121 |
| CellFX® Percutaneous Electrode (PE) System | DEVICE | Approved | Thyroid Nodule (Benign) | COMPLETED | NCT06117085 |
| Cryosurgery Liquid Nitrogen Sprayer | DEVICE | Approved | Warts | COMPLETED | NCT04738734 |
| CellFX System Device | DEVICE | Approved | Warts | COMPLETED | NCT04738734 |
| CellFX Device | DEVICE | Approved | Warts | COMPLETED | NCT04554394 |
| Intralesional Electrodesiccation | DEVICE | Approved | Skin Lesion | COMPLETED | NCT04539886 |
| CellFX System | DEVICE | Approved | BCC - Basal Cell Carcinoma | COMPLETED | NCT04918381 |
| Nano-Pulse Stimulation (NPS) | DEVICE | Approved | Sebaceous Hyperplasia | TERMINATED | NCT04253418 |
| Nano-Pulse Stimulation Device | DEVICE | Approved | Skin Lesion | COMPLETED | NCT03612570 |